Outcomes 2019 - Baylor Scott & White Heart and Vascular Hospital BSWHHVH_646_2019 Outcomes JOOMAG MOD | Page 31

Since the early beginnings of TAVR, Robert Stoler, MD, medical director
of the cardiac catheterization lab and co-director of the Division of
Cardiology, and Paul Grayburn, MD, administrative director of the non-
invasive lab, have conducted transcatheter mitral and aortic valve
studies leading to FDA approval of new technologies for patients.
Dr. Stoler and Dr. Grayburn are also known to proctor others in start-
up TAVR programs internationally and nationally, sharing knowledge
from the multidisciplinary Dallas campus program.
Center for Valve Disorders medical staff team (FY19):
James Choi, MD, FACC, FSCAI
Paul A. Grayburn, MD, FACC
Baron Hamman, MD
Robert F. Hebeler, Jr, MD, FACS
Albert Carl Henry III, MD, FACS
Stuart Lander, MD, FACC
Aldo Rafael, MD
Robert C. Stoler, MD, FACC, FSCAI
Ravi Vallabhan, MD, FACC, FSCAI
Haojie Wang, MD, PhD, FACC, RPVI
For fiscal year 2020, the team will include Dan Enter, MD.
Aortic valve research trials:
• EXCEED-Edwards CENTERA Transcatheter Heart Valve (THV) System
in symptomatic patients who are intermediate operative risk. There is
a bicuspid registry for this trial for patients with bicuspid morphology.
• Low-risk Bicuspid – Evolut PRO/Evolut R systems in patients with
severe bicuspid aortic valve stenosis
• Low-risk CoreValve/Evolut trial
• Early TAVR for asymptomatic patients using the Edwards
Sapien valve
Minimally invasive mitral valve therapies
For years, open heart surgery was the only treatment option for
mitral regurgitation—when the heart’s mitral valve doesn’t close
tightly, allowing blood to flow backward into the heart. Through
the advancement of research and the clinical trials conducted by
cardiologists on the medical staff at Baylor Scott & White Heart and
Vascular Hospital – Dallas, mitral regurgitation can be treated using
devices placed through a small incision in the groin.
TAVRs since 2011:
1,015
Percutaneous mitral valve
procedures since 2011:
95
Median length of stay (FY19) :
1 day
Readmission rate (FY19) :
<6%
Post-minimally invasive
valve replacement
patients discharged
home with no additional
care required (FY19) :
>90%
TAVR in-hospital
mortality rate (to date):
0.004%
Femoral access in TAVR
patients (FY19) :
98%
Mitral valve research trials: Minimally invasive mitral
valve repair in-hospital
mortality rate (FY19) :
The Dallas campus is one of the highest volume sites using MitraClip ® ,
and was involved in its initial trial, the COAPT Trial, which led to the
evolution of this device. Femoral access in
minimally invasive mitral
valve repair patients (FY19) :
• Abbott SUMMIT/Tendyne™ trial — Transcatheter mitral valve
replacement
• Apollo — Medtronic Intrepid™ trial for severe mitral regurgitation
Baylor Scott & White Heart and Vascular Hospital – Dallas continues
to be one of the top volume centers in the US for commercial and
research minimally invasive valve repair and replacement procedures.
0%
100%
Minimally invasive aortic valve therapies
31